“An Unrelenting Disaster Zone”: Merck’s Alzheimer’s Drug Fails in Phase III
Alzheimer's drug development took another hit. Source: BioSpace
Meet the Little-Known Chinese CAR-T Biotech Up More Than 500% Since June 2017
The company reported positive results from early studies in 35 patients with a type of blood cancer last year. Source: BioSpace
FDA Berates Bayer for Inadequate Cleaning, QC Questions at HQ
The company is addressing the FDA’s complaints regarding manufacturing practices, which stem from a routine inspection in January, Source: BioSpace
Jobs Affected as ImmunoGen Winds Down Ops at Massachusetts Facility
ImmunoGen gave a pipeline progress report and 2017 operating results last week. Source: BioSpace
Japan's Astellas Pays $102.5M for U.S. Biotech Universal Cells
Astellas will gain Universal Cells' proprietary Universal Donor Cell technology to create cell therapy products that do not require HLA matching. Source: BioSpace
Bayer Facility Warned for GMP Noncompliance
The FDA issued a warning letter to Bayer arising from an inspection at a Bayer Pharma facility in North Rhine-Westphalia, Germany. Source: Drug Industry Daily
Allergan Agrees to Settle Botox Antitrust Case for $13.45 Million
Allergan agreed to pay a class of doctors $13.45 million over claims the company artificially maintained the price of Botox through a deal with a potential competitor. Source: Drug Industry…
Drugmaker Payments to Advocacy Groups May Have Fueled Opioid Epidemic, Senator Asserts
Leading U.S. opioid manufacturers donated millions of dollars to organizations that doubled as advocacy groups, potentially fueling the opioid epidemic, according to the latest report to emerge from the opioids…
Sens. McCain, Baldwin Ask Trump to Support Bill on Drug Price Increases
Two senators called on the Trump administration to back a bill requiring drugmakers to justify any proposed price increases — invoking the president’s commitment in the State of the Union…
Industry Groups Welcome Administration’s FDA Budget Request, With Some Reservations
The White House’s proposed budget for fiscal 2019 drew mixed reviews from pharma industry groups, who praised steps they say will improve access but warned the proposal does not properly…
- Go to the previous page
- 1
- …
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- …
- 26
- Go to the next page